Cargando…

CD123 AML targeting by chimeric antigen receptors: A novel magic bullet for AML therapeutics?

Chimeric antigen receptor (CAR) modified T cells have emerged as powerful tools for controlling leukemias. We recently showed that anti-CD123 CAR-expressing cytokine-induced killer T cell treatment is an effective immunotherapeutic approach to eradicate Acute Myeloid Leukemia (AML) cells. Here, we d...

Descripción completa

Detalles Bibliográficos
Autores principales:	Tettamanti, Sarah, Biondi, Andrea, Biagi, Ettore, Bonnet, Dominique
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Landes Bioscience 2014
Materias:	Author's View
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4106165/ https://www.ncbi.nlm.nih.gov/pubmed/25083319 http://dx.doi.org/10.4161/onci.28835

Ejemplares similares

Lessons learned from a highly-active CD22-specific chimeric antigen receptor
por: Long, Adrienne H., et al.
Publicado: (2013)

Chimeric antigen receptor T-cell therapy for T-ALL and AML
por: Wei, Wenwen, et al.
Publicado: (2022)

Engineered chimeric antigen receptor-expressing T cells for the treatment of pancreatic ductal adenocarcinoma
por: Beatty, Gregory L
Publicado: (2014)

Adoptive immunotherapy for AML with CD123-engager T cells
por: Bonifant, Challice, et al.
Publicado: (2015)

CD123 Is Consistently Expressed on NPM1-Mutated AML Cells
por: Perriello, Vincenzo Maria, et al.
Publicado: (2021)

Chimeric Antigen Receptor (CAR) T Cell Therapy in Acute Myeloid Leukemia (AML)
por: Hofmann, Susanne, et al.
Publicado: (2019)

Bicistronic CAR-T cells targeting CD123 and CLL1 for AML to reduce the risk of antigen escape
por: Xie, Danni, et al.
Publicado: (2023)

Immunogenic and tolerogenic effects of the chimeric IL-2-diphtheria toxin cytocidal agent Ontak(®) on CD25(+) cells
por: Lutz, Manfred B, et al.
Publicado: (2014)

Extending the chimeric receptor-based T-cell targeting strategy to solid tumors
por: Rossig, Claudia
Publicado: (2013)

Survival outcomes of CD34(+)CD38(−)LSCs and their expression of CD123 in adult AML patients
por: Zahran, Asmaa M., et al.
Publicado: (2018)

Beyond the magic bullet
por: Lawrence, Christopher
Publicado: (1980)

The magic bullet: Niclosamide
por: Jiang, Haowen, et al.
Publicado: (2022)

Long peptide-based cancer immunotherapy targeting tumor antigen-specific CD4(+) and CD8(+) T cells
por: Tomita, Yusuke, et al.
Publicado: (2013)

Radioimmunotherapy of Non-Hodgkin’s Lymphoma: From the ‘Magic Bullets’ to ‘Radioactive Magic Bullets’
por: Chamarthy, Murthy R., et al.
Publicado: (2011)

Catch me if you can: how AML and its niche escape immunotherapy
por: Tettamanti, Sarah, et al.
Publicado: (2021)

New advances in leukaemia immunotherapy by the use of Chimeric Artificial Antigen Receptors (CARs): state of the art and perspectives for the near future
por: Biagi, Ettore, et al.
Publicado: (2011)

Magic bullets, magic shields, and antimicrobials in between
por: Prathapan, Praveen
Publicado: (2023)

Antigen-Based Immune Therapeutics for Type 1 Diabetes: Magic Bullets or Ordinary Blanks?
por: Culina, Slobodan, et al.
Publicado: (2011)

Chimeric Antigen Receptor (CAR)-Modified Immune Effector Cell Therapy for Acute Myeloid Leukemia (AML)
por: Acharya, Utkarsh H., et al.
Publicado: (2020)

Is radioimmunotherapy a 'magic bullet'?
por: Kim, Sung-Hyun
Publicado: (2012)

Oxytocin is needed, but it is no magic bullet
por: Weeks, AD
Publicado: (2016)

Magnetic Bead—Magic Bullet
por: Ruffert, Christine
Publicado: (2016)

CD44v6 chimeric antigen receptor T cell specificity towards AML with FLT3 or DNMT3A mutations
por: Tang, Ling, et al.
Publicado: (2022)

SIRPα-αCD123 fusion antibodies targeting CD123 in conjunction with CD47 blockade enhance the clearance of AML-initiating cells
por: Tahk, Siret, et al.
Publicado: (2021)

Malaria: moving beyond the search for magic bullets
por: Levashina, Elena, et al.
Publicado: (2023)

Novel CD123 polyaptamer hydrogel edited by Cas9/sgRNA for AML-targeted therapy
por: Wu, Haibin, et al.
Publicado: (2021)

P520: POINT OF CARE CD19 CHIMERIC ANTIGEN RECEPTOR (CAR) T-CELLS FOR RELAPSED/REFRACTORY ACUTE MYELOID LEUKEMIA (AML) WITH ABERRANT CD19 ANTIGEN EXPRESSION
por: Danylesko, Ivetta, et al.
Publicado: (2023)

Immunocytokines: the long awaited therapeutic magic bullet in rheumatoid arthritis?
por: van de Loo, Fons A, et al.
Publicado: (2009)

Transgenic Expression of IL15 Retains CD123-Redirected T Cells in a Less Differentiated State Resulting in Improved Anti-AML Activity in Autologous AML PDX Models
por: Mu-Mosley, Hong, et al.
Publicado: (2022)

Development of a novel universal immune receptor for antigen targeting: To Infinity and beyond
por: Urbanska, Katarzyna, et al.
Publicado: (2012)

The IL-15-based superagonist ALT-803 promotes the antigen-independent conversion of memory CD8(+) T cells into innate-like effector cells with antitumor activity
por: Wong, Hing C, et al.
Publicado: (2013)

Artemisinin Antimalarials: Preserving the “Magic Bullet”
por: Maude, Richard J, et al.
Publicado: (2010)

Nanobody: The “Magic Bullet” for Molecular Imaging?
por: Chakravarty, Rubel, et al.
Publicado: (2014)

Inaugural Editorial: Searching for Magic Bullets
por: Ho, Mitchell
Publicado: (2018)

Nanocarriers as Magic Bullets in the Treatment of Leukemia
por: Houshmand, Mohammad, et al.
Publicado: (2020)

Passive Immunization: Toward Magic Bullets
por: Marcotte, Harold, et al.
Publicado: (2015)

Do You Believe in Magic (Bullets)?
por: French, Jacqueline A.
Publicado: (2020)

CD123 target validation and preclinical evaluation of ADCC activity of anti-CD123 antibody CSL362 in combination with NKs from AML patients in remission
por: Xie, L H, et al.
Publicado: (2017)

Analysis of Subset Chimerism for MRD-Detection and Pre-Emptive Treatment in AML
por: Georgi, Julia-Annabell, et al.
Publicado: (2022)

Autophagy-assisted antigen cross-presentation: Autophagosome as the argo of shared tumor-specific antigens and DAMPs
por: Yi, Yongxiang, et al.
Publicado: (2012)

Cannot write session to /tmp/vufind_sessions/sess_uc94kfdlgump3eql3sf4m057a7